ASTRIS: a global real-world study of osimertinib in > 3000 patients with EGFR T790M positive non-small-cell lung cancer
Nenhuma Miniatura disponível
Citações na Scopus
47
Tipo de produção
article
Data de publicação
2019
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUTURE MEDICINE LTD
Autores
MARINIS, Filippo de
WU, Yi-Long
CHANG, Gee-Chen
CHEN, Yuh-Min
CHO, Byoung Chul
FREITAS, Helano C.
JIANG, Liyan
KIM, Sang-We
MARTIN, Claudio
Citação
FUTURE ONCOLOGY, v.15, n.26, p.3003-3014, 2019
Resumo
Aim: Osimertinib is a third-generation, irreversible, oral EGFR tyrosine kinase inhibitor. We report real-world effectiveness and safety data. Patients & methods: EGFR T790M positive advanced non-small-cell lung cancer adults, who received >= 1 prior EGFR tyrosine kinase inhibitor, received osimertinib 80 mg daily. Primary effectiveness outcome: overall survival. Secondary effectiveness outcomes included: investigato-rassessed clinical response, progression-free survival, time-to-treatment discontinuation. Results: At data cutoff, 3015 patients had enrolled: 57.1% had investigator-assessed response (95% CI: 55.2-58.9). Median progression-free survival: 11.1 months (95% CI: 11.0-12.0) and median time- to-treatment discontinuation: 13.5 months (95% CI: 12.6-13.9). Interstitial lung disease/pneumonitis-like events reported in 28 (1%) patients. Conclusion: Osimertinib demonstrated clinical effectiveness similar to efficacy observed in the clinical trial program with no new safety signals. Lay abstract: Osimertinib is a drug used to treat a type of non-small-cell lung cancer with a change (mutation) in a gene called EGFR. We studied 3015 adults with non-small-cell lung cancer containing a specific EGFR mutation called T790M. The patients had osimertinib treatment once a day. Prior to receiving a new supply of tablets (every 6 weeks), patients were checked to see if the osimertinib treatment was helping to treat their cancer and if they were experiencing any side effects. Osimertinib appeared to reduce the size of cancerous growths (tumors) in most patients (57%). On average, patients had 11.1 months of osimertinib treatment before their cancer worsened. The effectiveness and side effects of osimertinib treatment seen in this study were similar to previous studies with osimertinib.
Palavras-chave
ASTRIS, EGFR-TKI, lung cancer, molecular-targeted therapy, osimertinib, real world evidence, T790M
Referências
- Ahn MJ, 2019, CANCER-AM CANCER SOC, V125, P892, DOI 10.1002/cncr.31891
- Bordi P, 2015, TRANSL LUNG CANCER R, V4, P584, DOI 10.3978/j.issn.2218-6751.2015.08.09
- Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337
- EMA, 2018, SUMMARY PRODUCT CHAR
- FDA, 2018, HIGHL PRESCR INF
- Goss G, 2016, LANCET ONCOL, V17, P1643, DOI 10.1016/S1470-2045(16)30508-3
- Hanna N, 2017, J CLIN ONCOL, V35, P3484, DOI 10.1200/JCO.2017.74.6065
- Ilie M, 2016, TRANSL LUNG CANCER R, V5, P420, DOI 10.21037/tlcr.2016.08.06
- Jenkins S, 2017, J THORAC ONCOL, V12, P1061, DOI 10.1016/j.jtho.2017.04.003
- Mino-Kenudson M, 2016, TRANSL LUNG CANCER R, V5, P424, DOI 10.21037/tlcr.2016.08.01
- Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674
- Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
- Planchard D, 2018, ANN ONCOL, V29, P192, DOI 10.1093/annonc/mdy275
- Ramalingam SS, 2018, J CLIN ONCOL, V36, P841, DOI 10.1200/JCO.2017.74.7576
- Reungwetwattana T, 2018, J CLIN ONCOL, V36, P3290, DOI 10.1200/JCO.2018.78.3118
- Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X
- Santos ES, 2018, ONCOL THER, V6, P45, DOI 10.1007/s40487-018-0061-y
- Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806
- Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137
- Stockley T, 2018, CURR ONCOL, V25, P163, DOI 10.3747/co.25.4044
- Wang ZF, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4075-5
- Wu YL, 2018, J CLIN ONCOL, V36, P2702, DOI 10.1200/JCO.2018.77.9363
- Yang JCH, 2017, J CLIN ONCOL, V35, P1288, DOI 10.1200/JCO.2016.70.3223